Acadian Asset Management
NPCE icon

Acadian Asset Management’s Neuropace NPCE Stock Holding History

Acadian Asset Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,245
Closed -$49K – 2181
2025
Q4 		$49K Buy
+3,245
New +$43.4K ﹤0.01% 1796
2024
Q4 		– Sell
-3,566
Closed -$24K – 1998
2024
Q3 		$24K Sell
3,566
-65,352
-95% -$478K ﹤0.01% 1953
2024
Q2 		$520K Buy
68,918
+21,703
+46% +$219K ﹤0.01% 1186
2024
Q1 		$621K Buy
+47,215
New +$673K ﹤0.01% 959

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Acadian Asset Management's NPCE Position: Q1 2026 in Review

Acadian Asset Management sold out of Neuropace (NPCE) in Q1 2026, closing a stake of 3,245 shares — an estimated $49K sold.

Acadian Asset Management first reported a position in NPCE in Q1 2024 and held it in 4 quarters. The position peaked at $621K in Q1 2024. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Acadian Asset Management reported no remaining Neuropace position as of Q1 2026 after selling out during the quarter.
  • Acadian Asset Management sold 3,245 Neuropace shares in Q1 2026, an estimated $49K.
  • Acadian Asset Management first reported a position in Neuropace in Q1 2024 and held it in 4 quarters.
  • Acadian Asset Management's Neuropace position peaked at $621K in Q1 2024.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.